Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1298-1305

  Takawa, Masashi ^a,b   Masuda, Ken ^a   Kunizaki, Masaki ^c   Daigo, Yataro ^a,d   Takagi, Katsunori ^c   Iwai, Yukiko ^a   Cho, Hyun Soo ^a   Toyokawa, Gouji ^a   Yamane, Yuka ^a   Maejima, Kazuhiro ^a   Field, Helen I ^e   Kobayashi, Takaaki ^b   Akasu, Takayuki ^f   Sugiyama, Masanori ^b   Tsuchiya, Eijyu ^g,h   Atomi, Yutaka ^b   Ponder, Bruce A J ^e   Nakamura, Yusuke ^a   Hamamoto, Ryuji ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g SAITAMA CANCER CENTER   (Japan)

^h KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79959267832     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01958.x     Document Type: Article

References (42)

1. Zhao Q, Shentu J, Xu N et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2010: doi:. [Epub ahead of print.]
2. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005; 5: 447-58.
3. Hamamoto R, Furukawa Y, Morita M et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004; 6: 731-40.
4. Hamamoto R, Silva FP, Tsuge M et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 2006; 97: 113-8.
5. Kunizaki M, Hamamoto R, Silva FP et al. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res 2007; 67: 10759-65.
6. Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y, Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene 2008; 27: 2686-92.
7. Tsuge M, Hamamoto R, Silva FP et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet 2005; 37: 1104-7.
8. Volkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie 2007; 89: 1-20.
9. Jenuwein T, Laible G, Dorn R, Reuter G. SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell Mol Life Sci 1998; 54: 80-93.
10. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001; 21: 4330-6.
11. Boyer LA, Plath K, Zeitlinger J et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441: 349-53.
12. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-36.
13. Lee TI, Jenner RG, Boyer LA et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125: 301-13.
14. Gould A. Functions of mammalian Polycomb group and trithorax group related genes. Curr Opin Genet Dev 1997; 7: 488-94.
15. Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev 2002; 12: 210-8.
16. Kato T, Daigo Y, Hayama S et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005; 65: 5638-46.
17. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22: 2192-205.
18. Taniwaki M, Daigo Y, Ishikawa N et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006; 29: 567-75.
19. Ishikawa N, Daigo Y, Yasui W et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363-70.
20. Ishikawa N, Takano A, Yasui W et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007; 67: 11601-11.
21. Kusaba T, Nakayama T, Yamazumi K et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005; 58: 833-8.
22. Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011; 128: 574-86.
23. Hayami S, Yoshimatsu M, Veerakumarasivam A et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 2010; 9: 59.
24. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 2009; 101: 98-105.
25. Yoshimatsu M, Toyokawa G, Hayami S et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011; 128: 562-73.
26. Callagy G, Cattaneo E, Daigo Y et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003; 12: 27-34.
27. Callagy G, Pharoah P, Chin SF et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005; 205: 388-96.
28. Chin SF, Daigo Y, Huang HE et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003; 56: 275-9.
29. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14: 1639-48.
30. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005; 75: 252-7.
31. Fluge O, Gravdal K, Carlsen E et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009; 101: 1282-9.
32. Kikuchi J, Kinoshita I, Shimizu Y et al. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010; 116: 3015-24.
33. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005; 11: 8570-6.
34. Weikert S, Christoph F, Kollermann J et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005; 16: 349-53.
35. Ragno R, Simeoni S, Castellano S et al. Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J Med Chem 2007; 50: 1241-53.
36. Spannhoff A, Heinke R, Bauer I et al. Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem 2007; 50: 2319-25.
37. Cheng D, Yadav N, King RW, Swanson MS, Weinstein EJ, Bedford MT. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 2004; 279: 23892-9.
38. Miyazawa M, Ohsawa R, Tsunoda T et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 2010; 101: 433-9.
39. Yoshida K, Nakamura Y. Therapeutic cancer vaccines against gastro-intestinal cancer. Nippon Shokakibyo Gakkai Zasshi 2010; 107: 1255-61.
40. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-73.
41. Collett K, Eide GE, Arnes J et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12: 1168-74.
42. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007; 67: 547-56.